---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-056196"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:15:50.298683+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allarity raises ~$11M in public offering; reprices warrants, reduces Series A conversion price, redeems 3i holdings

## Summary
- Public offering of 357,223 shares, pre-funded warrants for 2,087,222 shares, and common warrants for 2,444,445 shares at $4.50 combined price, gross proceeds ~$11M.
- Concurrent with offering, repriced April 2023 common warrants exercise price to $4.50 and extended expiry to July 10, 2028.
- Converted Series A Preferred Stock conversion price reduced from $8.00 to $4.50.
- Using offering proceeds, redeemed 4,630 Series A Preferred shares from 3i, LP for $5,000,400 and a $350,000 secured note for $350,886.
- Placement agent A.G.P./Alliance Global Partners received 7% cash fee plus up to $150,000 expenses.

## SEC filing metadata
- accession: 0001213900-23-056196
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/ea181570-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-056196
- JSON: https://secwatch.observer/filing/0001213900-23-056196.json
- Plain text: https://secwatch.observer/filing/0001213900-23-056196.txt

## Key facts
- Governance Changes
  Allarity Therapeutics, Inc.: Reduced conversion price of Series A Convertible Preferred Stock from $8.00 to $4.50 via Third Certificate of Amendment to Amended and Restated Certificate of Designations (effective 2023-07-11).
  - Change: charter amendment
  - Effective: 2023-07-11
  source text: On July 11, 2023, we filed a Third Amendment to change the “Conversion Price” from $8.00 to $4.50.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Purchase Agreement with the Purchasers valued at approximately $11 million (effective 2023-07-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Value: approximately $11 million
  - Effective: 2023-07-05
  source text: On July 5, 2023, Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) agreed to sell in a public offering an aggregate of 357,223 shares of Common Stock of the Company (the “Shares”), pre-funded warrants to purchase up to 2,087,222 shares of Common Stock (the “Pre-Funded Warrants”), and common warrants to purchase up to 2,444,445 shares of Common Stock (the “Common Warrants” together with the Shares, the Pre-Funded Warrants and Common Stock issuable upon exercise of the Common Warrants and the Pre-Funded Warrants, collectively, the “Securities”), at an effective combined purchase price of $4.50 per share and related Common Warrant (the “Purchase Price”), for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and offering expenses payable by the Company (the “Offering”). The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto (each, a “Pu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. amended Amended and Restated Common Stock Purchase Warrant with the investors who acquired securities in the April Offering (effective 2023-07-10).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: the investors who acquired securities in the April Offering
  - Effective: 2023-07-10
  source text: Concurrent with the close of the Offering, the Company entered into an Amended and Restated Common Stock Purchase Warrant to memorialize the repricing and the extension of termination date (“Amended and Restated Warrant”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-07-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Effective: 2023-07-05
  source text: Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.